Literature DB >> 29268364

Editorial on "Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer".

Chia-Ju Liu1, Wei Lu2.   

Abstract

Entities:  

Year:  2017        PMID： 29268364      PMCID： PMC5723886          DOI： 10.21037/jtd.2017.09.117

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   3.005


× No keyword cloud information.
  24 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography.

Authors:  S Ngamruengphong; V K Sharma; B Nguyen; A Das
Journal:  Dis Esophagus       Date:  2009-06-09       Impact factor: 3.429

Review 3.  Outcomes in the management of esophageal cancer.

Authors:  Subroto Paul; Nasser Altorki
Journal:  J Surg Oncol       Date:  2014-08-21       Impact factor: 3.454

4.  Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?

Authors:  Helen M Heneghan; Claire Donohoe; Jessie Elliot; Zuhair Ahmed; Vinod Malik; Narayamasamy Ravi; John V Reynolds
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

5.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.

Authors:  Paul M Schneider; Ralf Metzger; Hartmut Schaefer; Frank Baumgarten; Daniel Vallbohmer; Jan Brabender; Eva Wolfgarten; Elfriede Bollschweiler; Stephan E Baldus; Hans P Dienes; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

7.  The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.

Authors:  Peter S N van Rossum; David V Fried; Lifei Zhang; Wayne L Hofstetter; Marco van Vulpen; Gert J Meijer; Laurence E Court; Steven H Lin
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

Review 8.  Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.

Authors:  Peter S N van Rossum; Lucas Goense; Jihane Meziani; Johannes B Reitsma; Peter D Siersema; Frank P Vleggaar; Marco van Vulpen; Gert J Meijer; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Gastrointest Endosc       Date:  2015-11-26       Impact factor: 9.427

9.  Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.

Authors:  Hao Zhang; Shan Tan; Wengen Chen; Seth Kligerman; Grace Kim; Warren D D'Souza; Mohan Suntharalingam; Wei Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

10.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.